Flemingsberg Science Foundation at Almedalen

We at the foundation have spent a sunny week in Almedalen 2024. It was a week filled with many insights and exciting discussions, and a highlight for us was our roundtable discussion, which we organized together with Huddinge Municipality. There, we delved into Flemingsberg’s significance for southern Stockholm as a world-leading player in life science. Pernilla Boström, COO of the Flemingsberg Science Foundation, shares more.

“It was very inspiring to lead and participate in the roundtable discussion we organized together with Huddinge Municipality about Flemingsberg’s significance for southern Stockholm as a world-leading player in life science. Sharing insights and experiences with a group of wise individuals from different perspectives was extremely rewarding.”

“I left Almedalen tired and satisfied, with many new impressions. I have had the privilege to participate, contribute, and be inspired alongside colleagues and partners. It has been a bustling exchange of knowledge, opportunities to influence and make a difference, and generous conversations and meetings – both formal and informal. The days were long, but I am already looking forward to next year’s Almedalen Week.”

The purpose of the roundtable discussion was to raise awareness about Flemingsberg’s development in life science and create a platform for the exchange of experiences. We shared valuable insights on how Flemingsberg can become one of Sweden’s most significant centers for education, research, and creativity. A discussion that we hope will continue even after Almedalen.

Watch our film with interviews and a summary of the discussion.

ANA Futura further strengthens Campus Flemingsberg

ANA Futura is officially inaugurated at Campus Flemingsberg – a unique research environment focused on bringing down boundaries: boundaries between research and education, as well as between academia and the community.

New multi-million kronor agreement for Sprint Bioscience

Sprint Bioscience and LG Chem have signed a cooperation and licensing agreement for research, development and commercialization of drug candidates. “We’re delighted about the agreement with LG Chem, an ideal partner to further develop this programme,” says Dr Anders Åberg, Sprint Bioscience CEO.

Go to Top